<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664504</url>
  </required_header>
  <id_info>
    <org_study_id>3332019055</org_study_id>
    <nct_id>NCT04664504</nct_id>
  </id_info>
  <brief_title>A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk</brief_title>
  <official_title>A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jing Jin, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal&#xD;
      Cancer Based on Recurrence Risk&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For patients with locally advanced rectal cancer, radiotherapy and chemotherapy combined with&#xD;
      surgery can improve the curative effect. Rectal magnetic resonance imaging (MRI) can be used&#xD;
      to stratify the risk of locally advanced rectal cancer before treatment. In this study, we&#xD;
      planned to use rectal MRI parameters and the possibility of patients with anal preservation&#xD;
      to group, and to observe the R0 resection rate and disease-free survival rate of patients&#xD;
      with stage II / III rectal cancer after individualized preoperative radiotherapy and&#xD;
      chemotherapy combined with radical surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>1 year</time_frame>
    <description>R0 resection rate is R0 resection probability of radical surgery in patients with locally advanced rectal cancer after individualized chemoradiotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3y OS</measure>
    <time_frame>3 years</time_frame>
    <description>3-year overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3yDMFS</measure>
    <time_frame>3 years</time_frame>
    <description>3-year distant metastatic free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3yLRRFS</measure>
    <time_frame>3 years</time_frame>
    <description>3-year locoregional recurrence-free survival</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Group CRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>concurrent chemoradiotherapy → TME → adjuvant chemotherapy (control group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group SCRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Short-course radiotherapy→ consolidation chemotherapy → TME (experimental group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group es-SCRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Local dose increase of Short-course radiotherapy→ consolidation chemotherapy → TME (experimental group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Concurrent Chemoradiotherapy Radiotherapy</intervention_name>
    <description>50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. Concurrent chemotherapy: Capecitabine 1650 mg/m2/d.</description>
    <arm_group_label>Group CRT</arm_group_label>
    <other_name>CRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Short-course Radiotherapy</intervention_name>
    <description>25Gy in 5 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.</description>
    <arm_group_label>Group SCRT</arm_group_label>
    <other_name>SCRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Local dose increase of Short-course Radiotherapy</intervention_name>
    <description>25Gy in 5 fractions to the of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes. And 4Gy in 1 fractions to the PGTV of primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.</description>
    <arm_group_label>Group es-SCRT</arm_group_label>
    <other_name>es-SCRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Consolidation chemotherapy</intervention_name>
    <description>Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 4 cycles. 4 courses*3 weeks per course.</description>
    <arm_group_label>Group SCRT</arm_group_label>
    <arm_group_label>Group es-SCRT</arm_group_label>
    <other_name>XEOLX*4 courses</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant chemotherapy</intervention_name>
    <description>2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles. 6 courses*3 weeks per course</description>
    <arm_group_label>Group CRT</arm_group_label>
    <other_name>XEOLX*6 courses</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TME</intervention_name>
    <description>Total mesorectal excision</description>
    <arm_group_label>Group CRT</arm_group_label>
    <arm_group_label>Group SCRT</arm_group_label>
    <arm_group_label>Group es-SCRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Rectal adenocarcinoma confirmed by histopathology&#xD;
&#xD;
          2. MRI staging was stage II / III (cT3-T4N0 or cT2-4N+)&#xD;
&#xD;
          3. The age is 18-75 years old, no gender limit&#xD;
&#xD;
        3) The distance between the lower limit of the lesion and the anal margin was less than or&#xD;
        equal to 10 cm 4) Karnofsky score ≥ 80 or ECOG score 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of other malignant tumors;&#xD;
&#xD;
          2. They were allergic to 5-FU, platinum, etc;&#xD;
&#xD;
          3. The patient is in thrombolytic and anticoagulant therapy, and has bleeding quality or&#xD;
             coagulation dysfunction; or in the past year, aneurysm, stroke, transient ischemic&#xD;
             attack, arteriovenous malformation occurred;&#xD;
&#xD;
          4. After the previous renal history, proteinuria or clinical renal function were found to&#xD;
             be abnormal;&#xD;
&#xD;
          5. History of gastrointestinal fistula, perforation or severe ulcer;&#xD;
&#xD;
          6. At present, there are active infection; clinical obvious heart disease; New York Heart&#xD;
             Association (NYHA) ≥ grade II congestive heart failure; unstable symptomatic&#xD;
             arrhythmia or peripheral vascular disease ≥ grade II; myocardial infarction and&#xD;
             cerebrovascular accident occurred within 6 months before enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuan Tang, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Chinese Academy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuan Tang, M.D.</last_name>
    <phone>+8615011304945</phone>
    <email>tangyuan82@162.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan Tang, MD</last_name>
      <phone>0086-15011304945</phone>
      <email>tangyuan82@162.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 6, 2020</study_first_submitted>
  <study_first_submitted_qc>December 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>June 6, 2021</last_update_submitted>
  <last_update_submitted_qc>June 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jing Jin, M.D.</investigator_full_name>
    <investigator_title>Clinical Professor, Radiotherapy Department</investigator_title>
  </responsible_party>
  <keyword>Rectal Cancer</keyword>
  <keyword>Neoadjuvant Chemoradiotherapy</keyword>
  <keyword>Recurrence Risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

